Luye Pharma Group Ltd.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: BMG570071099
HKD
2.26
0.02 (0.89%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
The United Laboratories International Holdings Ltd.
China Medical System Holdings Ltd.
Grand Pharmaceutical Group Ltd.
Simcere Pharmaceutical Group Ltd.
Hygeia Healthcare Holdings Co., Ltd.
Luye Pharma Group Ltd.
SSY Group Ltd.
China Traditional Chinese Medicine Holdings Co. Ltd.
HUTCHMED (China) Ltd.
Akeso, Inc.
Keymed Biosciences, Inc.

Why is Luye Pharma Group Ltd. ?

1
Flat results in Dec 25
  • INTEREST(HY) At HKD 381.13 MM has Grown at 23.73%
  • DEBTORS TURNOVER RATIO(HY) Lowest at 1.33 times
  • RAW MATERIAL COST(Y) Grown by 8.27% (YoY)
2
With ROE of 1.46%, it has a Very Expensive valuation with a 0.61 Price to Book Value
  • Over the past year, while the stock has generated a return of 8.13%, its profits have risen by 115.6%
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Icon
No Data Found
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
44.52%
EBIT Growth (5y)
27.20%
EBIT to Interest (avg)
10.89
Debt to EBITDA (avg)
0.35
Net Debt to Equity (avg)
0.18
Sales to Capital Employed (avg)
0.10
Tax Ratio
11.47%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
13.67%
ROE (avg)
10.54%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
42
Industry P/E
Price to Book Value
0.61
EV to EBIT
38.37
EV to EBITDA
27.58
EV to Capital Employed
0.62
EV to Sales
4.30
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
1.63%
ROE (Latest)
1.46%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

6What is working for the Company
NET PROFIT(Q)

At HKD 335.28 MM has Grown at 153.74%

DEBT-EQUITY RATIO (HY)

Lowest at 3.37 %

OPERATING PROFIT(Q)

Highest at HKD 1,143.9 MM

OPERATING PROFIT MARGIN(Q)

Highest at 33.41 %

PRE-TAX PROFIT(Q)

Highest at HKD 555.14 MM

-6What is not working for the Company
INTEREST(HY)

At HKD 381.13 MM has Grown at 23.73%

DEBTORS TURNOVER RATIO(HY)

Lowest at 1.33 times

RAW MATERIAL COST(Y)

Grown by 8.27% (YoY

INVENTORY TURNOVER RATIO(HY)

Lowest at 2.29 times

Here's what is working for Luye Pharma Group Ltd.

Net Profit
At HKD 335.28 MM has Grown at 153.74%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is very positive

Net Profit (HKD MM)

Operating Profit
Highest at HKD 1,143.9 MM
in the last five periods
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (HKD MM)

Operating Profit Margin
Highest at 33.41 %
in the last five periods
MOJO Watch
Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit
Highest at HKD 555.14 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (HKD MM)

Debt-Equity Ratio
Lowest at 3.37 %
in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Depreciation
At HKD 472.23 MM has Grown at 7.72%
period on period (QoQ)
MOJO Watch
The expenditure on assets done by the company has gone into productive use which should positively reflect in the future sales

Depreciation (HKD MM)

Here's what is not working for Luye Pharma Group Ltd.

Interest
At HKD 381.13 MM has Grown at 23.73%
over previous Semi-Annual period
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (HKD MM)

Debtors Turnover Ratio
Lowest at 1.33 times and Fallen
In each half year in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Inventory Turnover Ratio
Lowest at 2.29 times
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Raw Material Cost
Grown by 8.27% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales